Fresenius Medical Care

Still a long way to go

12/07/24 -"We have huge doubts that FRE25 will achieve the planned profitability (group adjusted EBIT: 10-14%) by 2025 as there are numerous obstacles. The management has already indicated that the effects of ..."

PDF page sample
Pages
56
Language
English
Published on
12/07/24
Download
You may also be interested by these reports :
21/01/25
While 2024 has been challenging for Western MedTech firms with significant exposure to China, 2025 is also expected to be subdued. The ongoing ...
17/01/25
When we last pushed the family-controlled and second largest hearing aid player, Demant’s (Add; Denmark) investment case in September 2023, the firm ...
07/01/25
At AlphaValue, Health is a sector that pertains to anything that is not Pharma. This regroups hearing aids, eye surgery, retirement homes, etc. The ...
18/12/24
Philips continues to recover from the major (regulatory) setbacks associated with sleep apnea device recalls and a series of other product quality ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO